Trial Profile
A Randomized Phase II Trial to Assess the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency (HRD Patients With Deleterious BRCA1/2 Tumor or Germline Mutation and/or HRD Score High)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Feb 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Carboplatin; Cyclophosphamide; Epirubicin; Paclitaxel
- Indications Carcinoma; Early breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms GeparOla
- 12 Oct 2020 Primary endpoint (response by pCR =ypT0/is ypN0) has not been met.
- 12 Oct 2020 Results published in the Annals of Oncology.
- 21 Sep 2020 Results (n=105) assessing germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer, presented at the 45th European Society for Medical Oncology Congress